PFE ▼ -0.5% - Pfizer Inc. $PFE Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study. The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 (≥75% reduction in the Eczema Area and Severity Index) at Wk 16 across all evaluated doses 01-OCT-2026 05:54 AM ET